Survey of Oncologists in Europe to Evaluate Their Knowledge of KRAS Testing
The survey will be conducted for 3 rounds in months 0, 12, and 24 after the first interview.
Before the beginning of the study, a sampling list will be created by merging lists of
oncologists (and their contact information) to be collected from Cegedim, the European
Society of Medical Oncology (ESMO), and from major cancer centers and oncology clinics in 5
countries of Europe, including France, Germany, Italy, Spain and the Czech Republic.
In each round of the survey, potential participating oncologists will be sampled from each
country's sampling list through random sampling and reached through telephone, letter or
email. During the initial contact, the oncologists will be assessed for their eligibility to
participate in the study by using a standardized screening questionnaire.
The initial contact and screening of potential participating oncologists will continue until
a total of 150 eligible oncologists agree to participate in each round. The number of
oncologists recruited in each country will be proportional to the use of Vectibix. The
minimum and maximum for the number of oncologists in each country for each round of survey
are proposed to be: 35-50 for France and Germany; 15-35 for Italy and Spain and 10-15 for
Czech Republic. We will attempt to sample the numbers of oncologists in each country
according to these ranges. Each eligible oncologist can only answer the survey questions in
1 of the 3 rounds of survey.
Study staff will then conduct the survey with each of the identified eligible oncologists
over the telephone, using a standardized questionnaire. Information about their awareness
of the correct indication and appropriate administration of Vectibix and their experience in
the administration of Vectibix treatment in the previous 6 months will be collected. We
will make every attempt to collect the correct information from participating oncologists.
This may require at least two phone calls to allow an oncologist to review their notes in
order to report the correct data.
Time Perspective: Cross-Sectional
Proportion of oncologists who are aware of the correct indication of Vectibix, with regard to tumor KRAS status and who conduct a KRAS test prior to initiation of Vectibix treatment
Trend survey of physicians performed over 3 years
France: French Data Protection Authority